CorMedix Inc. (CRMD) stock
CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 15/3087% below fair value
$4.66−0.18 (-3.72%)
Close on Nov 13, 2026Market cap $363.22MP/E –Yield –
CorMedix gross margin
Gross margin is gross profit as a percentage of revenue.
CorMedix's gross margin for the twelve months ending Sep 30, 2026 was 77.5%. For fiscal 2025 it was 88.5%, against 92.7% the year before. The highest annual figure on record is 94.3% in fiscal 2022.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 88.5% | −4.2 |
| FY2024 | Dec 31, 2024 | 92.7% | −1.6 |
| FY2022 | Dec 31, 2022 | 94.3% | +72.3 |
| FY2021 | Dec 31, 2021 | 22.0% | +7.6 |
| FY2020 | Dec 31, 2020 | 14.4% | +46.1 |
| FY2019 | Dec 31, 2019 | -31.8% | −39.4 |
| FY2018 | Dec 31, 2018 | 7.7% | −57.4 |
| FY2017 | Dec 31, 2017 | 65.1% | +128.7 |
| FY2016 | Dec 31, 2016 | -63.6% | −11.9 |
| FY2015 | Dec 31, 2015 | -51.7% | +83.9 |
| FY2014 | Dec 31, 2014 | -135.5% | +9839.7 |
| FY2013 | Dec 31, 2013 | -9975.2% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 55.0% | −34.2 |
| Q2 FY2026 | Jun 30, 2026 | 75.7% | −19.6 |
| Q1 FY2026 | Mar 31, 2026 | 82.5% | −13.4 |
| Q4 FY2025 | Dec 31, 2025 | 83.4% | −12.8 |
| Q3 FY2025 | Sep 30, 2025 | 89.3% | −4.7 |
| Q2 FY2025 | Jun 30, 2025 | 95.3% | +58.6 |
| Q1 FY2025 | Mar 31, 2025 | 95.9% | −2.7 |
| Q4 FY2024 | Dec 31, 2024 | 96.2% | +17.8 |
| Q3 FY2024 | Sep 30, 2024 | 94.0% | −4.4 |
| Q2 FY2024 | Jun 30, 2024 | 36.8% | −43.2 |
| Q4 FY2022 | Dec 31, 2022 | 98.6% | +83.8 |
| Q3 FY2022 | Sep 30, 2022 | 78.5% | +44.5 |
| Q2 FY2022 | Jun 30, 2022 | 98.4% | +174.6 |
| Q1 FY2022 | Mar 31, 2022 | 80.0% | +49.5 |
| Q4 FY2021 | Dec 31, 2021 | 14.9% | +17.6 |
| Q3 FY2021 | Sep 30, 2021 | 33.9% | +19.8 |
| Q2 FY2021 | Jun 30, 2021 | -76.1% | −59.5 |
| Q1 FY2021 | Mar 31, 2021 | 30.5% | −4.0 |
| Q4 FY2020 | Dec 31, 2020 | -2.7% | +83.4 |
| Q3 FY2020 | Sep 30, 2020 | 14.1% | +46.8 |
| Q2 FY2020 | Jun 30, 2020 | -16.7% | −56.8 |
| Q1 FY2020 | Mar 31, 2020 | 34.5% | +73.1 |
| Q4 FY2019 | Dec 31, 2019 | -86.2% | −102.8 |
| Q3 FY2019 | Sep 30, 2019 | -32.7% | −48.9 |
| Q2 FY2019 | Jun 30, 2019 | 40.1% | +385.9 |
| Q1 FY2019 | Mar 31, 2019 | -38.6% | −15.5 |
| Q4 FY2018 | Dec 31, 2018 | 16.6% | −151.8 |
| Q3 FY2018 | Sep 30, 2018 | 16.1% | +25.3 |
| Q2 FY2018 | Jun 30, 2018 | -345.8% | −432.6 |
| Q1 FY2018 | Mar 31, 2018 | -23.1% | +113.4 |
| Q4 FY2017 | Dec 31, 2017 | 168.4% | +138.7 |
| Q3 FY2017 | Sep 30, 2017 | -9.1% | – |
| Q2 FY2017 | Jun 30, 2017 | 86.7% | – |
| Q1 FY2017 | Mar 31, 2017 | -136.5% | – |
| Q4 FY2016 | Dec 31, 2016 | 29.8% | – |
See a number that looks wrong?